Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Assets Average (2021 - 2025)

InMed Pharmaceuticals' Assets Average history spans 5 years, with the latest figure at $12.3 million for Q4 2025.

  • For Q4 2025, Assets Average rose 29.45% year-over-year to $12.3 million; the TTM value through Dec 2025 reached $12.3 million, up 29.45%, while the annual FY2025 figure was $13.7 million, 5.68% up from the prior year.
  • Assets Average reached $12.3 million in Q4 2025 per INM's latest filing, down from $14.5 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $18.4 million in Q4 2021 to a low of $8.9 million in Q1 2025.
  • Average Assets Average over 5 years is $13.6 million, with a median of $13.7 million recorded in 2022.
  • The largest YoY upside for Assets Average was 29.85% in 2025 against a maximum downside of 37.86% in 2025.
  • A 5-year view of Assets Average shows it stood at $18.4 million in 2021, then fell by 14.18% to $15.8 million in 2022, then dropped by 16.92% to $13.1 million in 2023, then decreased by 27.53% to $9.5 million in 2024, then increased by 29.45% to $12.3 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Assets Average are $12.3 million (Q4 2025), $14.5 million (Q3 2025), and $12.4 million (Q2 2025).